| Title |
IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases
|
|---|---|
| Published in |
Radiotherapy & Oncology, May 2015
|
| DOI | 10.1016/j.radonc.2015.05.008 |
| Pubmed ID | |
| Authors |
Peter Hoskin, Ana Rojas, Elena Fidarova, Rakesh Jalali, Ana Mena Merino, Adela Poitevin, Seam Oucrif, Sherif Abdelwahab, Lotfi Kochbati, Aista Plieskiene, Francesc Casas, Susana Stojanovic, Günther Schneider, Branislav Jeremic |
| Abstract |
To determine the optimal single-dose radiotherapy schedule for pain from bone metastases in a multi-centre, international, randomised trial. 651 patients were randomised to either 8Gy (n=325) or 4Gy (n=326) radiotherapy. Pain at 4, 8, 12, 24 and 52weeks was assessed using a Categorical Scale (CS) and a Visual Analogue Scale (VAS). The primary endpoint was response at 4weeks. There was no significant difference in patient demographics and other co-variates. The complete response (CR) rate and ORR (complete or partial response) for all follow-up times were higher after 8Gy (p=0.02). The Kaplan-Meier actuarial rate (categorical scale) at 4weeks for ORR was 80% after 8Gy compared to 68% after 4Gy (p=0.0015). 117 re-treatments were given of which 72 were in the 4Gy group and 45 in 8Gy arm (p=0.01). There was a marked consistent difference in pain relief at all time points in favour of 8Gy. These data reinforce the case for single dose 8Gy radiotherapy to be recommended for metastatic bone pain in all healthcare settings. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | 2% |
| Unknown | 45 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 20% |
| Student > Ph. D. Student | 8 | 17% |
| Researcher | 7 | 15% |
| Student > Master | 4 | 9% |
| Student > Doctoral Student | 3 | 7% |
| Other | 11 | 24% |
| Unknown | 4 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 72% |
| Nursing and Health Professions | 2 | 4% |
| Physics and Astronomy | 2 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 7 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2015.
All research outputs
#16,048,318
of 25,374,917 outputs
Outputs from Radiotherapy & Oncology
#2,808
of 4,846 outputs
Outputs of similar age
#149,051
of 280,169 outputs
Outputs of similar age from Radiotherapy & Oncology
#21
of 54 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,846 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,169 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.